Top of this page
Skip navigation, go straight to the content
Our Science
•
Pipeline
R&D pipeline
The UCB pipeline delivers:
- a promising portfolio targeting severe diseases and addressing unmet medical needs
- focus on neurological and immunological diseases
- more convenient and effective treatments for patients and specialists.
Neurology
Immunology
| Indications | Phase 1 | Phase 2 | Phase 3 | Filed | ||
|---|---|---|---|---|---|---|
| bimekizumab (IL17AF) | psoriasis |  | ||||
| psoriatic arthritis |  | |||||
| axial spondyloarthritis | | |||||
| hidradenitis suppurativa |  | |||||
| padsevonil (PPSI) | epilepsy – drug resistant |  | ||||
| zilucoplan (C5) | myasthenia gravis |  | ||||
| other |  | |||||
| rozanolixizumab (FcRn) | myasthenia gravis | | ||||
| immune thrombocytopenia | | |||||
| chronic inflammatory demyelinating polyneuropathy (CIDP) |  | |||||
| dapirolizumab pegol (CD40L)* | systemic lupus erythematosus |  | ||||
| UCB0107 (Tau) | Progressive Supranuclear Palsy (PSP) | | ||||
| UCB0599 | Parkinson's disease |  | ||||
| UCB7858 | auto-inflammatory diseases |  | ||||
* | In collaboration with Biogen |